{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:15:50Z","timestamp":1788383750140,"version":"build-2803163510"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","award":["YTP-SYSUCC-0010"],"award-info":[{"award-number":["YTP-SYSUCC-0010"]}],"id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","award":["CIRP-SYSUCC-0005"],"award-info":[{"award-number":["CIRP-SYSUCC-0005"]}],"id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.lanwpc.2026.101852","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:37:38Z","timestamp":1787009858000},"page":"101852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Epstein\u2013Barr virus based biomarkers and targeted therapies in nasopharyngeal carcinoma: a narrative review"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6899-7007","authenticated-orcid":false,"given":"Sen-Yu","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9823-4651","authenticated-orcid":false,"given":"Ren-Jia","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8654-3636","authenticated-orcid":false,"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1137-9349","authenticated-orcid":false,"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lanwpc.2026.101852_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101852_bib2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41392-025-02197-9","article-title":"Viral oncogenesis in cancer: from mechanisms to therapeutics","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101852_bib4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/(SICI)1097-0142(19980801)83:3<582::AID-CNCR29>3.0.CO;2-R","article-title":"The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma","volume":"83","author":"Marks","year":"1998","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101852_bib5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1701717","article-title":"Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer","volume":"377","author":"Chan","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101852_bib6","doi-asserted-by":"crossref","first-page":"e251895","DOI":"10.1001\/jamanetworkopen.2025.1895","article-title":"Patient characteristics and treatment outcomes of nasopharyngeal carcinoma in nonendemic regions","volume":"8","author":"Alsavaf","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"23","key":"10.1016\/j.lanwpc.2026.101852_bib7","doi-asserted-by":"crossref","first-page":"768","DOI":"10.21037\/atm.2019.11.75","article-title":"The effect of histological subtypes on survival outcome in nasopharyngeal carcinoma after extensive follow up","volume":"7","author":"Wu","year":"2019","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/microorganisms12010014","article-title":"Recent advances in assessing the clinical implications of epstein-barr virus infection and their application to the diagnosis and treatment of nasopharyngeal carcinoma","volume":"12","author":"Yoshizaki","year":"2023","journal-title":"Microorganisms"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101852_bib9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.bjc.6603609","article-title":"Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma","volume":"96","author":"Ji","year":"2007","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib10","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1186\/s12879-025-11204-x","article-title":"A single-center retrospective analysis of serological and molecular findings in patients infected with Epstein-Barr virus","volume":"25","author":"Gao","year":"2025","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.lanwpc.2026.101852_bib11","series-title":"Managing Infections in Patients With Hematological Malignancies","first-page":"14","article-title":"Viruses","author":"Martin","year":"2010"},{"issue":"2","key":"10.1016\/j.lanwpc.2026.101852_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1348-0421.2011.00410.x","article-title":"Host factors associated with the kinetics of Epstein-Barr virus DNA load in patients with primary Epstein-Barr virus infection","volume":"56","author":"Nakai","year":"2012","journal-title":"Microbiol Immunol"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12935-021-01862-7","article-title":"The diagnostic value of EBV-DNA and EBV-related antibodies detection for nasopharyngeal carcinoma: a meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101852_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/jnci\/djad012","article-title":"Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions","volume":"115","author":"Lam","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"26","key":"10.1016\/j.lanwpc.2026.101852_bib15","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1200\/JCO.22.01979","article-title":"Performance and operational feasibility of Epstein-Barr virus-based screening for detection of nasopharyngeal carcinoma: direct comparison of two alternative approaches","volume":"41","author":"Lou","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101852_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx007","article-title":"Current state of PCR-based Epstein-Barr virus DNA testing for nasopharyngeal cancer","volume":"109","author":"Kim","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101852_bib17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/aje\/kws404","article-title":"Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern China","volume":"177","author":"Liu","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"10","key":"10.1016\/j.lanwpc.2026.101852_bib18","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/annonc\/mdz231","article-title":"Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China","volume":"30","author":"Ji","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101852_bib19","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/clinchem\/hvac032","article-title":"Utility of Epstein-Barr virus DNA in nasopharynx swabs as a reflex test to triage seropositive individuals in nasopharyngeal carcinoma screening programs","volume":"68","author":"Chen","year":"2022","journal-title":"Clin Chem"},{"issue":"9","key":"10.1016\/j.lanwpc.2026.101852_bib20","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa2301496","article-title":"Anti-Epstein-Barr virus BNLF2b for mass screening for nasopharyngeal cancer","volume":"389","author":"Li","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib21","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1038\/s41467-019-11226-5","article-title":"Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases","volume":"10","author":"Lam","year":"2019","journal-title":"Nat Commun"},{"issue":"22","key":"10.1016\/j.lanwpc.2026.101852_bib22","doi-asserted-by":"crossref","first-page":"E5115","DOI":"10.1073\/pnas.1804184115","article-title":"Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma","volume":"115","author":"Lam","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"44","key":"10.1016\/j.lanwpc.2026.101852_bib23","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2209852119","article-title":"Epigenetic analysis of cell-free DNA by fragmentomic profiling","volume":"119","author":"Zhou","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101852_bib24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccell.2025.02.002","article-title":"Fragmentomics profiling and quantification of plasma Epstein-Barr virus DNA enhance prediction of future nasopharyngeal carcinoma","volume":"43","author":"Lam","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.23.01296","article-title":"Impact of an Epstein-Barr virus serology-based screening program on nasopharyngeal carcinoma mortality: a cluster-randomized controlled trial","volume":"43","author":"Chen","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.lanwpc.2026.101852_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116237","article-title":"DDX3X mutation and Epstein-Barr virus cooperate to induce R-loop-dependent oncogenesis","volume":"44","author":"Cai","year":"2025","journal-title":"Cell Rep"},{"issue":"26","key":"10.1016\/j.lanwpc.2026.101852_bib27","doi-asserted-by":"crossref","first-page":"16688","DOI":"10.1074\/jbc.272.26.16688","article-title":"A CACCC box-like cis-regulatory element of the Epstein-Barr virus ED-L2 promoter interacts with a novel transcriptional factor in tissue-specific squamous epithelia","volume":"272","author":"Nakagawa","year":"1997","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.lanwpc.2026.101852_bib28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/path.5249","article-title":"Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker","volume":"247","author":"Lam","year":"2019","journal-title":"J Pathol"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101852_bib29","first-page":"1188","article-title":"Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma","volume":"59","author":"Lo","year":"1999","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101852_bib30","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1084\/jem.169.6.2191","article-title":"Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren's syndrome","volume":"169","author":"Saito","year":"1989","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1186\/s12885-021-08408-0","article-title":"Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41598-016-0006-3","article-title":"Comparison of circulating tumour cells and circulating cell-free Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma undergoing radiotherapy","volume":"6","author":"Vo","year":"2016","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101852_bib33","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jmoldx.2023.03.007","article-title":"Comparison of real-time PCR and digital PCR for detection of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma","volume":"25","author":"Miller","year":"2023","journal-title":"J Mol Diagn"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib34","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1186\/s12885-025-14539-5","article-title":"Diagnostic performance of EBV DNA load testing for nasopharyngeal carcinoma in nasopharyngeal swab outperforms the approach in other specimens","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.lanwpc.2026.101852_bib35","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1158\/1078-0432.CCR-12-2897","article-title":"Epstein-Barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment","volume":"19","author":"Adham","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101852_bib36","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1128\/JCM.02308-06","article-title":"Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus in peripheral blood","volume":"45","author":"Hakim","year":"2007","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib37","first-page":"52","article-title":"Comparison of whole blood and plasma for monitoring cytomegalovirus and Epstein-Barr virus","volume":"47","author":"Fukuda","year":"2024","journal-title":"New Microbiol"},{"issue":"5","key":"10.1016\/j.lanwpc.2026.101852_bib38","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1515\/cclm-2018-0733","article-title":"The rational specimen for the quantitative detection of Epstein-Barr virus DNA load","volume":"57","author":"Kedi","year":"2019","journal-title":"Clin Chem Lab Med"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101852_bib39","article-title":"Plasma Epstein-Barr virus DNA and risk of future nasopharyngeal cancer","volume":"2","author":"Chan","year":"2023","journal-title":"NEJM Evi"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101852_bib40","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/cam4.1381","article-title":"Dynamic changes in plasma Epstein-Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study","volume":"7","author":"He","year":"2018","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101852_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104513","article-title":"Advances in individualization of systemic treatment for locoregionally advanced nasopharyngeal carcinoma: a systematic review","volume":"10","author":"Blanchard","year":"2025","journal-title":"ESMO Open"},{"issue":"18_Supplement","key":"10.1016\/j.lanwpc.2026.101852_bib42","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.AACRAHNS23-PO-008","article-title":"Abstract PO-008: association of plasma Epstein-Barr virus DNA and clinical response in patients with recurrent and\/or metastatic nasopharyngeal cancer treated with pembrolizumab or standard-of-care chemotherapy in KEYNOTE-122","volume":"29","author":"Chan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.lanwpc.2026.101852_bib43","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/jnci\/94.21.1614","article-title":"Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma","volume":"94","author":"Chan","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"34","key":"10.1016\/j.lanwpc.2026.101852_bib44","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1200\/JCO.2006.07.7982","article-title":"Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma","volume":"24","author":"Leung","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.lanwpc.2026.101852_bib45","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.ijrobp.2007.02.012","article-title":"Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy","volume":"68","author":"Lin","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.lanwpc.2026.101852_bib46","article-title":"Prognostic impact of plasma Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma treated using intensity-modulated radiation therapy","volume":"6","author":"Peng","year":"2016","journal-title":"Sci Rep"},{"issue":"29","key":"10.1016\/j.lanwpc.2026.101852_bib47","doi-asserted-by":"crossref","first-page":"47780","DOI":"10.18632\/oncotarget.17822","article-title":"Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area","volume":"8","author":"Alfieri","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101852_bib48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/jrr\/rrw128","article-title":"Prevalence and significance of plasma Epstein-Barr virus DNA level in nasopharyngeal carcinoma","volume":"58","author":"Prayongrat","year":"2017","journal-title":"J Radiat Res"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101852_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.29882","article-title":"Development of a nomogram model for treatment of nonmetastatic nasopharyngeal carcinoma","volume":"3","author":"Zhang","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.lanwpc.2026.101852_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104628","article-title":"Pretreatment 18F-FDG PET\/CT texture parameters provide complementary information to Epstein-Barr virus DNA titers in patients with metastatic nasopharyngeal carcinoma","volume":"104","author":"Lin","year":"2020","journal-title":"Oral Oncol"},{"issue":"2","key":"10.1016\/j.lanwpc.2026.101852_bib51","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/jmv.27440","article-title":"Cell-free EBV DNA as a biomarker during clinical management of nasopharyngeal carcinoma in a nonendemic region","volume":"94","author":"Pramanik","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.lanwpc.2026.101852_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.105972","article-title":"Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma","volume":"131","author":"Zong","year":"2022","journal-title":"Oral Oncol"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101852_bib53","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0587","article-title":"Association of plasma Epstein-Barr virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 immunotherapy","volume":"5","author":"Xu","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"14","key":"10.1016\/j.lanwpc.2026.101852_bib54","doi-asserted-by":"crossref","first-page":"14979","DOI":"10.1002\/cam4.6132","article-title":"Prognostic effect of residual plasma Epstein-Barr viral DNA after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma","volume":"12","author":"Zheng","year":"2023","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.lanwpc.2026.101852_bib55","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijrobp.2019.01.007","article-title":"Plasma Epstein-Barr virus DNA load after induction chemotherapy predicts outcome in locoregionally advanced nasopharyngeal carcinoma","volume":"104","author":"Huang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib56","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12916-022-02463-5","article-title":"Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics","volume":"20","author":"Lv","year":"2022","journal-title":"BMC Med"},{"issue":"5","key":"10.1016\/j.lanwpc.2026.101852_bib57","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ccell.2025.01.014","article-title":"Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: a multicenter phase 2 PLATINUM trial","volume":"43","author":"Xu","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lanwpc.2026.101852_bib58","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3389\/fonc.2020.01417","article-title":"Prognostication of half-life clearance of plasma EBV DNA in previously untreated non-metastatic nasopharyngeal carcinoma treated with radical intensity-modulated radiation therapy","volume":"10","author":"Chan","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.lanwpc.2026.101852_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2056","article-title":"911P Post-radiotherapy (RT) Epstein-Barr virus (EBV) DNA dynamics identifies optimal timepoint for stratification of high-risk nasopharyngeal carcinoma (NPC)","volume":"34","author":"Tan","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lanwpc.2026.101852_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106655","article-title":"Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma","volume":"148","author":"Neo","year":"2024","journal-title":"Oral Oncol"},{"key":"10.1016\/j.lanwpc.2026.101852_bib61","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1200\/jco.2013.31.15_suppl.6015","article-title":"Prognostication of survival from nasopharyngeal carcinoma by reduction of plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course: a new paradigm of prognostication","volume":"31","author":"Chan","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lanwpc.2026.101852_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217276","article-title":"Significance of longitudinal Epstein-Barr virus DNA combined with multipoint tumor response for dynamic risk stratification and treatment adaptation in nasopharyngeal carcinoma","volume":"605","author":"Liu","year":"2024","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101852_bib63","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/cam4.3669","article-title":"Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma","volume":"10","author":"Li","year":"2021","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib64","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1038\/s41467-019-11853-y","article-title":"Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma","volume":"10","author":"Lv","year":"2019","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.lanwpc.2026.101852_bib65","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.ccell.2024.07.001","article-title":"Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: the EP-SEASON study","volume":"42","author":"Lv","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lanwpc.2026.101852_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109721","article-title":"Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: a recursive partitioning risk stratification analysis","volume":"185","author":"Kong","year":"2023","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101852_bib67","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.annonc.2020.03.289","article-title":"Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy","volume":"31","author":"Hui","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.lanwpc.2026.101852_bib68","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41416-018-0026-9","article-title":"Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma","volume":"118","author":"Ma","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lanwpc.2026.101852_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106500","article-title":"The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma","volume":"145","author":"Wang","year":"2023","journal-title":"Oral Oncol"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101852_bib70","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.lanwpc.2026.101852_bib71","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.22.00327","article-title":"Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial","volume":"40","author":"Zhang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lanwpc.2026.101852_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113336","article-title":"Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: a single-arm, phase 2 trial","volume":"194","author":"Guo","year":"2023","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101852_bib73","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1200\/JCO.21.01467","article-title":"Deintensified chemoradiotherapy for pretreatment Epstein-Barr virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma: a phase II randomized noninferiority trial","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lanwpc.2026.101852_bib74","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231221343","article-title":"Combined pre-treatment and middle-treatment Epstein-Barr virus DNA load contributes to prognostication and treatment modification in nasopharyngeal carcinoma patients","volume":"16","author":"Lan","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101852_bib75","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(24)00504-7","article-title":"Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial","volume":"25","author":"Liu","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanwpc.2026.101852_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106938","article-title":"The efficacy of adjuvant chemotherapy in patients with different midpoint-radiotherapy Epstein-Barr virus DNA plasma loads","volume":"156","author":"Chen","year":"2024","journal-title":"Oral Oncol"},{"key":"10.1016\/j.lanwpc.2026.101852_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110032","article-title":"Oral chemotherapy versus observation alone in nasopharyngeal carcinoma patients with persistently detected circulating cell-free Epstein-Barr virus DNA during follow-up","volume":"190","author":"Huang","year":"2024","journal-title":"Radiother Oncol"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101852_bib78","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1001\/jamaoncol.2022.4656","article-title":"Adjuvant capecitabine following concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a randomized clinical trial","volume":"8","author":"Miao","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.lanwpc.2026.101852_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-026-10244-w","article-title":"Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma","author":"Lv","year":"2026","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.lanwpc.2026.101852_bib80","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.ijrobp.2008.07.062","article-title":"Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging","volume":"73","author":"Mao","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101852_bib81","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101852_bib82","doi-asserted-by":"crossref","first-page":"224","DOI":"10.6004\/jnccn.2022.0016","article-title":"NCCN Guidelines (R) insights: head and neck cancers, version 1.2022","volume":"20","author":"Caudell","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101852_bib83","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","article-title":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger)","volume":"32","author":"Bossi","year":"2021","journal-title":"Ann Oncol"},{"issue":"10445","key":"10.1016\/j.lanwpc.2026.101852_bib84","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.lanwpc.2026.101852_bib85","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.2025.1132","article-title":"Adjuvant PD-1 blockade with camrelizumab for nasopharyngeal carcinoma: the DIPPER randomized clinical trial","volume":"333","author":"Liang","year":"2025","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101852_bib86","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/s41571-025-01075-1","article-title":"Optimizing CAR T cell therapy for solid tumours: a clinical perspective","volume":"22","author":"Li","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.lanwpc.2026.101852_bib87","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamaoncol.2019.3869","article-title":"Development and use of the Anti-CD19 chimeric antigen receptor T-Cell therapy axicabtagene ciloleucel in large B-Cell lymphoma: a review","volume":"6","author":"Locke","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib88","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ijc.1430","article-title":"Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma","volume":"94","author":"Chua","year":"2001","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib89","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdh027","article-title":"Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma","volume":"15","author":"Comoli","year":"2004","journal-title":"Ann Oncol"},{"issue":"35","key":"10.1016\/j.lanwpc.2026.101852_bib90","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","article-title":"Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes","volume":"23","author":"Comoli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.lanwpc.2026.101852_bib91","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/CJI.0b013e3181f3cbf4","article-title":"Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma","volume":"33","author":"Louis","year":"2010","journal-title":"J Immunother"},{"issue":"5","key":"10.1016\/j.lanwpc.2026.101852_bib92","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/0008-5472.CAN-11-3399","article-title":"Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy","volume":"72","author":"Smith","year":"2012","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib93","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/mt.2013.242","article-title":"Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma","volume":"22","author":"Chia","year":"2014","journal-title":"Mol Ther"},{"issue":"14","key":"10.1016\/j.lanwpc.2026.101852_bib94","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1002\/cncr.30541","article-title":"Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma","volume":"123","author":"Huang","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib95","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41698-021-00162-7","article-title":"Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma","volume":"5","author":"Smith","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.lanwpc.2026.101852_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1208475","article-title":"Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma","volume":"14","author":"Secondino","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101852_bib97","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.annonc.2024.08.2344","article-title":"Gemcitabine, carboplatin, and Epstein\u2013Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial","volume":"35","author":"Toh","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.lanwpc.2026.101852_bib98","doi-asserted-by":"crossref","DOI":"10.4161\/23723556.2014.976507","article-title":"Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"4","author":"Li","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.lanwpc.2026.101852_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112965","article-title":"A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients","volume":"191","author":"Liang","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lanwpc.2026.101852_bib100","article-title":"899P Safety and efficacy of a novel CAR-T cell therapy (BRG01) targeting the Epstein-Barr virus envelope glycoprotein in advanced metastatic nasopharyngeal cancer patients","volume":"35","author":"Zhang","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101852_bib101","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.lanwpc.2026.101852_bib102","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1158\/1078-0432.CCR-12-0574","article-title":"Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors","volume":"18","author":"Wildeman","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101852_bib103","doi-asserted-by":"crossref","first-page":"468","DOI":"10.7555\/JBR.28.20140066","article-title":"T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo","volume":"28","author":"Tang","year":"2014","journal-title":"J Biomed Res"},{"key":"10.1016\/j.lanwpc.2026.101852_bib104","doi-asserted-by":"crossref","first-page":"9341","DOI":"10.2147\/OTT.S221040","article-title":"CD137 Co-Stimulation improves the antitumor effect of LMP1-Specific chimeric antigen receptor T cells in vitro and in vivo","volume":"12","author":"Tang","year":"2019","journal-title":"OncoTargets Ther"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101852_bib105","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/bjc.2017.475","article-title":"A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy","volume":"118","author":"Cho","year":"2018","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib106","doi-asserted-by":"crossref","DOI":"10.4161\/onci.22590","article-title":"Human MHC class I-restricted high avidity CD4(+) T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo","volume":"2","author":"Xue","year":"2013","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.lanwpc.2026.101852_bib107","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101852_bib108","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/blood.V99.7.2592","article-title":"Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication","volume":"99","author":"Comoli","year":"2002","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.lanwpc.2026.101852_bib109","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-137139","article-title":"Emerging role of adoptive T cell therapy for EBV induced nasopharyngeal carcinoma (NPC) - a systematic review","volume":"136","author":"Farooqi","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101852_bib110","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1158\/0008-5472.CAN-03-2196","article-title":"Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine","volume":"64","author":"Duraiswamy","year":"2004","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101852_bib111","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.4049\/jimmunol.177.7.4897","article-title":"Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope","volume":"177","author":"Smith","year":"2006","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.lanwpc.2026.101852_bib112","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1273311","article-title":"Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: phenotype and effector function of T cells impact on clinical response","volume":"6","author":"Smith","year":"2017","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.lanwpc.2026.101852_bib113","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.ymthe.2020.09.040","article-title":"Monocytic myeloid-derived suppressor cells underpin resistance to adoptive T cell therapy in nasopharyngeal carcinoma","volume":"29","author":"Hopkins","year":"2021","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.lanwpc.2026.101852_bib114","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s00262-022-03158-9","article-title":"Phase I study of expanded natural killer cells in combination with cetuximab for recurrent\/metastatic nasopharyngeal carcinoma","volume":"71","author":"Lim","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"43","key":"10.1016\/j.lanwpc.2026.101852_bib115","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022785","article-title":"Chemoradiotherapy combined with NK cell transfer in a patient with recurrent and metastatic nasopharyngeal carcinoma inducing long-term tumor control: a case report","volume":"99","author":"Jin","year":"2020","journal-title":"Medicine (Baltim)"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101852_bib116","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-21-2292","article-title":"EBV infection in epithelial malignancies induces resistance to antitumor natural killer cells via F3-Mediated platelet aggregation","volume":"82","author":"Duan","year":"2022","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101852_bib117","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/annonc\/mdr341","article-title":"A phase II study evaluating the safety and efficacy of an adenovirus-DeltaLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma","volume":"23","author":"Chia","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lanwpc.2026.101852_bib118","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.antiviral.2014.01.018","article-title":"Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome","volume":"104","author":"Lee","year":"2014","journal-title":"Antiviral Res"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101852_bib119","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10822-016-9899-y","article-title":"Computational analysis of EBNA1 \"druggability\" suggests novel insights for Epstein-Barr virus inhibitor design","volume":"30","author":"Gianti","year":"2016","journal-title":"J Comput Aided Mol Des"},{"issue":"9","key":"10.1016\/j.lanwpc.2026.101852_bib120","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/1087057110379154","article-title":"Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1","volume":"15","author":"Thompson","year":"2010","journal-title":"J Biomol Screen"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101852_bib121","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41551-017-0042","article-title":"EBNA1-targeted probe for the imaging and growth inhibition of tumours associated with the Epstein\u2013Barr virus","volume":"1","author":"Jiang","year":"2017","journal-title":"Nat Biomed Eng"},{"issue":"482","key":"10.1016\/j.lanwpc.2026.101852_bib122","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5612","article-title":"Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth","volume":"11","author":"Messick","year":"2019","journal-title":"Sci Transl Med"},{"issue":"52","key":"10.1016\/j.lanwpc.2026.101852_bib123","doi-asserted-by":"crossref","first-page":"26614","DOI":"10.1073\/pnas.1915372116","article-title":"Reactivation of Epstein-Barr virus by a dual-responsive fluorescent EBNA1-targeting agent with Zn(2+)-chelating function","volume":"116","author":"Jiang","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.lanwpc.2026.101852_bib124","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1158\/1078-0432.CCR-24-2814","article-title":"First-in-Human clinical trial of a small-molecule EBNA1 inhibitor, VK-2019, in patients with epstein-barr-positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic studies","volume":"31","author":"Colevas","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.lanwpc.2026.101852_bib125","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/nar\/gkm1080","article-title":"Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5","volume":"36","author":"Barth","year":"2008","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib126","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ijc.28007","article-title":"Targeting of DICE1 tumor suppressor by Epstein-Barr virus-encoded miR-BART3\u2217 microRNA in nasopharyngeal carcinoma","volume":"133","author":"Lei","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lanwpc.2026.101852_bib127","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fimmu.2020.00367","article-title":"Role of viral and host microRNAs in immune regulation of Epstein-Barr virus-associated diseases","volume":"11","author":"Iizasa","year":"2020","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.lanwpc.2026.101852_bib128","doi-asserted-by":"crossref","first-page":"7838","DOI":"10.18632\/oncotarget.3046","article-title":"Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma","volume":"6","author":"Cai","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101852_bib129","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1304338","article-title":"A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors","volume":"6","author":"Turrini","year":"2017","journal-title":"OncoImmunology"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101852_bib130","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1002\/jmv.24870","article-title":"Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model","volume":"89","author":"Novalic","year":"2017","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101852_bib131","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12951-023-02069-w","article-title":"LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion","volume":"21","author":"Xiang","year":"2023","journal-title":"J Nanobiotechnology"},{"issue":"8","key":"10.1016\/j.lanwpc.2026.101852_bib132","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1182\/blood-2002-10-3092","article-title":"Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma","volume":"101","author":"Duraiswamy","year":"2003","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.lanwpc.2026.101852_bib133","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.7150\/thno.42494","article-title":"A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"issue":"24","key":"10.1016\/j.lanwpc.2026.101852_bib134","doi-asserted-by":"crossref","first-page":"13105","DOI":"10.1128\/JVI.05598-11","article-title":"A virus-like particle-based Epstein-Barr virus vaccine","volume":"85","author":"Ruiss","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.lanwpc.2026.101852_bib135","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.actbio.2024.12.022","article-title":"Fluorinated polyethyleneimine vectors with serum resistance and adjuvant effect to deliver LMP2 mRNA vaccine for nasopharyngeal carcinoma therapy","volume":"192","author":"Yang","year":"2025","journal-title":"Acta Biomater"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101852_bib136","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1007\/s12274-022-5254-x","article-title":"A lipid-based LMP2-mRNA vaccine to treat nasopharyngeal carcinoma","volume":"16","author":"Guo","year":"2023","journal-title":"Nano Res"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606526000568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606526000568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:22:46Z","timestamp":1788380566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606526000568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":136,"alternative-id":["S2666606526000568"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2026.101852","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epstein\u2013Barr virus based biomarkers and targeted therapies in nasopharyngeal carcinoma: a narrative review","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2026.101852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2026.101900","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2026.101958","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2026.101957","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101852"}}